| Primary |
| Hiv Infection |
72.8% |
| Drug Use For Unknown Indication |
7.4% |
| Antiviral Prophylaxis |
5.9% |
| Antiretroviral Therapy |
4.5% |
| Prophylaxis |
2.2% |
| Antiviral Treatment |
1.4% |
| Product Used For Unknown Indication |
1.0% |
| Hiv Infection Cdc Category C3 |
0.5% |
| Hypertension |
0.5% |
| Retroviral Infection |
0.5% |
| Tuberculosis |
0.5% |
| Acquired Immunodeficiency Syndrome |
0.4% |
| Asymptomatic Hiv Infection |
0.4% |
| Intervertebral Disc Degeneration |
0.4% |
| Asthma |
0.3% |
| Bacterial Infection |
0.3% |
| Chronic Hepatitis C |
0.3% |
| Depression |
0.3% |
| Diabetes Mellitus |
0.3% |
| Ear Infection |
0.3% |
|
| Drug Exposure During Pregnancy |
11.8% |
| Vomiting |
11.2% |
| Myocardial Infarction |
8.6% |
| Lipodystrophy Acquired |
5.9% |
| Rash |
5.3% |
| Ventricular Septal Defect |
5.3% |
| Death |
4.6% |
| Drug Interaction |
4.6% |
| Intra-uterine Death |
4.6% |
| Stillbirth |
4.6% |
| Haematotoxicity |
3.9% |
| Premature Baby |
3.9% |
| Suicide Attempt |
3.9% |
| Hepatotoxicity |
3.3% |
| Maternal Exposure During Pregnancy |
3.3% |
| Pyrexia |
3.3% |
| Trisomy 18 |
3.3% |
| Weight Decreased |
3.3% |
| Drug Toxicity |
2.6% |
| Galactosaemia |
2.6% |
|
| Secondary |
| Hiv Infection |
53.6% |
| Drug Exposure During Pregnancy |
17.8% |
| Drug Use For Unknown Indication |
6.6% |
| Antiretroviral Therapy |
3.4% |
| Product Used For Unknown Indication |
2.7% |
| End Stage Aids |
2.0% |
| Asymptomatic Hiv Infection |
1.8% |
| Hepatitis C |
1.8% |
| Acquired Immunodeficiency Syndrome |
1.7% |
| Retroviral Infection |
1.5% |
| Maternal Exposure Timing Unspecified |
1.3% |
| Antiviral Treatment |
1.1% |
| Systemic Antiviral Treatment |
1.1% |
| Antiviral Prophylaxis |
0.6% |
| Coronary Artery Disease |
0.6% |
| Diabetes Mellitus |
0.6% |
| Hyperlipidaemia |
0.6% |
| Prophylaxis |
0.6% |
| Hiv Test Positive |
0.5% |
| Hiv Infection Cdc Group Iii |
0.4% |
|
| Trisomy 21 |
8.4% |
| Viral Mutation Identified |
8.4% |
| Ventricular Septal Defect |
6.9% |
| Coronary Artery Disease |
6.1% |
| Gastroschisis |
6.1% |
| Blood Creatine Phosphokinase Increased |
5.3% |
| Lipodystrophy Acquired |
5.3% |
| Premature Baby |
5.3% |
| Abortion Induced |
4.6% |
| Death |
4.6% |
| Polydactyly |
4.6% |
| Syncope |
4.6% |
| Adrenogenital Syndrome |
3.8% |
| Galactosaemia |
3.8% |
| Myocardial Infarction |
3.8% |
| Pruritus |
3.8% |
| Pulmonary Valve Stenosis |
3.8% |
| Trisomy 15 |
3.8% |
| Weight Decreased |
3.8% |
| Drug Exposure During Pregnancy |
3.1% |
|
| Concomitant |
| Hiv Infection |
57.3% |
| Drug Use For Unknown Indication |
11.4% |
| Drug Exposure During Pregnancy |
4.3% |
| Product Used For Unknown Indication |
4.3% |
| Acquired Immunodeficiency Syndrome |
2.9% |
| Pneumonia |
2.1% |
| Hypertension |
1.8% |
| Smoking Cessation Therapy |
1.8% |
| Systemic Antiviral Treatment |
1.8% |
| Antiretroviral Therapy |
1.5% |
| Pain |
1.5% |
| Depression |
1.4% |
| Hiv Test Positive |
1.4% |
| Hepatitis C |
1.3% |
| Asymptomatic Hiv Infection |
1.2% |
| Prophylaxis |
1.0% |
| Sleep Disorder |
0.9% |
| Blood Cholesterol Increased |
0.8% |
| Diabetes Mellitus |
0.8% |
| Tuberculosis |
0.7% |
|
| Rhabdomyolysis |
11.8% |
| Vomiting |
8.7% |
| Weight Decreased |
8.7% |
| Death |
6.3% |
| Osteonecrosis |
5.5% |
| Pancytopenia |
5.5% |
| Pregnancy |
5.5% |
| Reversible Ischaemic Neurological Deficit |
5.5% |
| Cholestasis |
4.7% |
| Cerebrovascular Accident |
3.9% |
| Liver Function Test Abnormal |
3.9% |
| Trisomy 15 |
3.9% |
| Viral Infection |
3.9% |
| Congenital Pulmonary Valve Atresia |
3.1% |
| Hip Dysplasia |
3.1% |
| Irritability |
3.1% |
| Lower Limb Fracture |
3.1% |
| Neuropathy Peripheral |
3.1% |
| Polydactyly |
3.1% |
| Progressive Multifocal Leukoencephalopathy |
3.1% |
|
| Interacting |
| Hiv Infection |
54.5% |
| Schizoaffective Disorder |
18.2% |
| Extrapyramidal Disorder |
9.1% |
| Intervertebral Disc Degeneration |
9.1% |
| Pain |
9.1% |
|
| Drug Interaction |
33.3% |
| Priapism |
33.3% |
| Weight Decreased |
33.3% |
|
